233 related articles for article (PubMed ID: 30557792)
1. Association of quality of life with disease characteristics and treatment outcomes in patients with advanced gastric cancer: Exploratory analysis of RAINBOW and REGARD phase III trials.
Chau I; Fuchs CS; Ohtsu A; Barzi A; Liepa AM; Cui ZL; Hsu Y; Al-Batran SE
Eur J Cancer; 2019 Jan; 107():115-123. PubMed ID: 30557792
[TBL] [Abstract][Full Text] [Related]
2. Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated gastric or gastroesophageal junction adenocarcinoma.
Al-Batran SE; Van Cutsem E; Oh SC; Bodoky G; Shimada Y; Hironaka S; Sugimoto N; Lipatov ON; Kim TY; Cunningham D; Rougier P; Muro K; Liepa AM; Chandrawansa K; Emig M; Ohtsu A; Wilke H
Ann Oncol; 2016 Apr; 27(4):673-9. PubMed ID: 26747859
[TBL] [Abstract][Full Text] [Related]
3. Quality of Life Associated with Ramucirumab Treatment in Patients with Advanced Gastric Cancer in Japan: Exploratory Analysis from the Phase III RAINBOW Trial.
Yamaguchi K; Shimada Y; Hironaka S; Sugimoto N; Komatsu Y; Nishina T; Omuro Y; Tamura T; Piao Y; Homma G; Jen MH; Liepa AM; Muro K
Clin Drug Investig; 2021 Jan; 41(1):53-64. PubMed ID: 33355909
[TBL] [Abstract][Full Text] [Related]
4. Health-related quality of life in advanced gastric/gastroesophageal junction cancer with second-line pembrolizumab in KEYNOTE-061.
Van Cutsem E; Amonkar M; Fuchs CS; Alsina M; Özgüroğlu M; Bang YJ; Chung HC; Muro K; Goekkurt E; Benson AB; Sun W; Wainberg ZA; Norquist JM; Chen X; Shih CS; Shitara K
Gastric Cancer; 2021 Nov; 24(6):1330-1340. PubMed ID: 34363528
[TBL] [Abstract][Full Text] [Related]
5. Tumor Response and Symptom Palliation from RAINBOW, a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer.
Cascinu S; Bodoky G; Muro K; Van Cutsem E; Oh SC; Folprecht G; Ananda S; Girotto G; Wainberg ZA; Miron MLL; Ajani J; Wei R; Liepa AM; Carlesi R; Emig M; Ohtsu A
Oncologist; 2021 Mar; 26(3):e414-e424. PubMed ID: 33274542
[TBL] [Abstract][Full Text] [Related]
6. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
[TBL] [Abstract][Full Text] [Related]
7. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 Study Group.
Ajani JA; Moiseyenko VM; Tjulandin S; Majlis A; Constenla M; Boni C; Rodrigues A; Fodor M; Chao Y; Voznyi E; Awad L; Van Cutsem E;
J Clin Oncol; 2007 Aug; 25(22):3210-6. PubMed ID: 17664468
[TBL] [Abstract][Full Text] [Related]
8. Quality of life with first-line pembrolizumab for PD-L1-positive advanced gastric/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 study.
Van Cutsem E; Valderrama A; Bang YJ; Fuchs CS; Shitara K; Janjigian YY; Qin S; Larson TG; Shankaran V; Stein S; Norquist JM; Kher U; Shah S; Alsina M
ESMO Open; 2021 Aug; 6(4):100189. PubMed ID: 34371381
[TBL] [Abstract][Full Text] [Related]
9. Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE).
Necchi A; Nishiyama H; Matsubara N; Lee JL; Petrylak DP; de Wit R; Drakaki A; Liepa AM; Mao H; Bell-McGuinn K; Powles T
BMC Urol; 2020 Nov; 20(1):181. PubMed ID: 33160359
[TBL] [Abstract][Full Text] [Related]
10. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
Brahmer JR; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Zhang J; Lubiniecki GM; Deitz AC; Rangwala R; Reck M
Lancet Oncol; 2017 Dec; 18(12):1600-1609. PubMed ID: 29129441
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic effect of Jinlongshe Granule () on quality of life of stage IV gastric cancer patients using EORTC QLQ-C30: A double-blind placebo-controlled clinical trial.
Sun DZ; Jiao JP; Zhang X; Xu JY; Ye M; Xiu LJ; Zhao Y; Lu Y; Liu X; Zhao J; Shi J; Qin ZF; Wei PK
Chin J Integr Med; 2015 Aug; 21(8):579-86. PubMed ID: 25399306
[TBL] [Abstract][Full Text] [Related]
12. Comparison of quality of life and worry of cancer recurrence between endoscopic and surgical treatment for early gastric cancer.
Choi JH; Kim ES; Lee YJ; Cho KB; Park KS; Jang BK; Chung WJ; Hwang JS; Ryu SW
Gastrointest Endosc; 2015 Aug; 82(2):299-307. PubMed ID: 25892060
[TBL] [Abstract][Full Text] [Related]
13. Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGS.
Tabernero J; Alsina M; Shitara K; Doi T; Dvorkin M; Mansoor W; Arkenau HT; Prokharau A; Ghidini M; Faustino C; Gorbunova V; Zhavrid E; Nishikawa K; Ando T; Yalçın Ş; Van Cutsem E; Sabater J; Skanji D; Leger C; Amellal N; Ilson DH
Gastric Cancer; 2020 Jul; 23(4):689-698. PubMed ID: 32128634
[TBL] [Abstract][Full Text] [Related]
14. Predictive factors for overall quality of life in patients with advanced cancer.
Cramarossa G; Chow E; Zhang L; Bedard G; Zeng L; Sahgal A; Vassiliou V; Satoh T; Foro P; Ma BB; Chie WC; Chen E; Lam H; Bottomley A
Support Care Cancer; 2013 Jun; 21(6):1709-16. PubMed ID: 23338229
[TBL] [Abstract][Full Text] [Related]
15. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
Wilke H; Muro K; Van Cutsem E; Oh SC; Bodoky G; Shimada Y; Hironaka S; Sugimoto N; Lipatov O; Kim TY; Cunningham D; Rougier P; Komatsu Y; Ajani J; Emig M; Carlesi R; Ferry D; Chandrawansa K; Schwartz JD; Ohtsu A;
Lancet Oncol; 2014 Oct; 15(11):1224-35. PubMed ID: 25240821
[TBL] [Abstract][Full Text] [Related]
16. Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW.
Muro K; Cho JY; Bodoky G; Goswami C; Chao Y; Dos Santos LV; Shimada Y; Topuzov E; Van Cutsem E; Tabernero J; Zalcberg J; Chau I; Cascinu S; Cheng R; Hsu Y; Emig M; Orlando M; Fuchs C
J Gastroenterol Hepatol; 2018 Apr; 33(4):814-824. PubMed ID: 28960444
[TBL] [Abstract][Full Text] [Related]
17. Treatment Patterns and Changes in Quality of Life during First-Line Palliative Chemotherapy in Korean Patients with Advanced Gastric Cancer.
Kim JW; Kim JG; Kang BW; Chung IJ; Hong YS; Kim TY; Song HS; Lee KH; Zang DY; Ko YH; Song EK; Baek JH; Koo DH; Oh SY; Cho H; Lee KW
Cancer Res Treat; 2019 Jan; 51(1):223-239. PubMed ID: 30584995
[TBL] [Abstract][Full Text] [Related]
18. Quality of life in patients with brain metastases using the EORTC QLQ-BN20+2 and QLQ-C15-PAL.
Caissie A; Nguyen J; Chen E; Zhang L; Sahgal A; Clemons M; Kerba M; Arnalot PF; Danjoux C; Tsao M; Barnes E; Holden L; Danielson B; Chow E
Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):1238-45. PubMed ID: 22172909
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer.
Bando H; Shimodaira H; Fujitani K; Takashima A; Yamaguchi K; Nakayama N; Takahashi T; Oki E; Azuma M; Nishina T; Hironaka S; Komatsu Y; Shitara K
Eur J Cancer; 2018 Mar; 91():86-91. PubMed ID: 29353164
[TBL] [Abstract][Full Text] [Related]
20. Depression-A Major Contributor to Poor Quality of Life in Patients With Advanced Cancer.
Grotmol KS; Lie HC; Hjermstad MJ; Aass N; Currow D; Kaasa S; Moum TÅ; Pigni A; Loge JH;
J Pain Symptom Manage; 2017 Dec; 54(6):889-897. PubMed ID: 28803091
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
